The Resmed CDI (ASX: RMD) share price is in focus after the company reported second quarter revenue up 11% to $1.4 billion and diluted earnings per share rising 15% to $2.68.
What did Resmed report?
- Revenue rose 11% year-over-year to $1,422.8 million (up 9% in constant currency).
- Gross margin increased by 320 basis points to 61.8% (non-GAAP: 62.3%).
- Income from operations grew 18% to $491.7 million (non-GAAP: up 19%).
- Net income came in at $392.6 million, up 14% from the prior year period.
- Diluted earnings per share were $2.68 (non-GAAP: $2.81), up 15% and 16% respectively.
- Quarterly dividend declared at US$0.60 per share; $88 million returned to shareholders.
What else do investors need to know?
Resmed’s second quarter growth was fuelled by robust demand for its sleep and respiratory care devices. Sales improved across most regions, with the US, Canada and Latin America seeing an 11% rise, and Europe and Asia posting 6% constant currency growth (excluding software).
The company reported a $6 million restructuring-related charge, linked to finalising workforce planning initiatives started earlier in the year. Despite slightly higher selling and administration costs, Resmed delivered strong operating cash flow of $340 million and continued its buyback program, repurchasing $175 million in shares.
What’s next for Resmed?
Heading into the second half of FY26, Resmed plans to increase investment in digital health solutions and innovation, aiming to expand global access to home-based care. The company is strategically focused on scaling up its AI-enabled technology, following recent FDA clearance for its Smart Comfort device.
Management maintains a goal of sustainable, profitable growth supported by further product development and capital returns, with continued emphasis on research, operational efficiencies, and global market expansion.
Resmed share price snapshot
Over the past 12 months, Resmed shares have declined 10%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 5% over the same period.
The post Resmed posts Q2 FY26 earnings growth, lifts dividend appeared first on The Motley Fool Australia.
Should you invest $1,000 in ResMed Inc. right now?
Before you buy ResMed Inc. shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and ResMed Inc. wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 Jan 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Atlas Arteria shares: Q4 2025 toll revenue jumps 9.5%
- Elders FY25 earnings: resilient profit and strategic growth
- Nine Entertainment shakes up portfolio: QMS buy, radio sale, and digital focus
- PLS Group books 49% revenue leap and strong cash flow in December quarter earnings
- The high flying ASX small-cap AI stock you need to pay attention to!
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.
Leave a Reply